Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
600 clinical trials found
Clinical trials

AMGEN

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma (NCT06376045)

Currently recruiting

Amgen 20230053

A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies (NCT06527404)

Currently recruiting

AML M22 PLATFORM

The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC) (ACTRN12619000280101)

Currently recruiting

AMLM23

A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy. (NCT03839771)

Currently recruiting

aMMbition

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combination with Daratumumab SC (Tec-D) Following Induction with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnosed Multiple Myeloma (NCT06577025)

Currently recruiting

AMT-116

First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors (NCT05725291)

Currently recruiting

AMT-253-01

First-in-Human, Phase 1 Study of AMT-253, an Anti-MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors (NCT05906862)

Currently recruiting

AN4

A double-blinded, 4-arm, covariate-adjusted adaptive clinical trial evaluating the efficacy of novel pharmacological agents for the treatment of anorexia nervosa in individuals aged 16 and over (ACTRN12623001019695p)

Currently recruiting

ANT-007

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER) [ANT-007] (NCT05171049)

Currently recruiting

ANT-008

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia) [ANT-008] (NCT05171075)

Currently recruiting

ANZHIT-2 study

A multi-centre, Australian and New Zealand, phase II exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (ANZHIT-2) (ACTRN12622001232729)

This study (ANZHIT-2) aims to improve the treatment protocols in haploidentical (half match) transplants. We will be using more targeted chemotherapy and total body irradiation in the transplants thus improving on their safety and success. We will also compare the cost-effectiveness and quality of life of haploidentical transplants to matched donor transplants.
Currently recruiting

AP30CP01

A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and/or in Combination with Azacitidine in Adults with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome with Excess Blasts (MDS-EB) (NCT06372717)

Currently recruiting

APG2575AU101

APG2575AU101 A Phase Ib/II Study of APG-2575 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS) (NCT04964518)

Currently recruiting

APM001

A Randomised, Double-Blind, Parallel-Group,Placebo-Controlled, 60-Week, Phase II Clinical Trial of Three Re-Purposed Medications in Moderate Severity Parkinson’s Disease (ACTRN12620000560998)

Currently recruiting

APM002

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinson’s Disease (ACTRN12623000843651)

Currently recruiting

App-delivered psychological treatment of IBS-in-IBD

Treatment of functional gut symptoms in patients with quiescent IBD and IBS - a single-blinded parallel trial assessing efficacy of app-delivered gut-directed hypnotherapy versus psycho-education (ACTRN12624000678594)

This trial will compare the effects of one of two app-delivered psychological programs on persistent gastrointestinal symptoms in people with inflammatory bowel disease in remission and persistent symptoms (termed IBS-in-IBD).
Currently recruiting

Aqua EFC17599

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis [AD] who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase [JAK] inhibitor treatment (NCT06241118)

Currently recruiting

Aravax - cashew/walnut/hazelnut

Discovery, design, and analysis of novel allergen peptide therapeutics (Trial Not Registered)

Blood samples from people with nut allergies – cashew, walnut and hazelnut. This is to research how a peptide immunotherapy can be developed for people with specific nut allergies. This is to overall support the discovery, design and future testing of peptide therapies.
Currently recruiting

ARGX-113-2315

A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Ocular Myasthenia Gravis [ADAPT oculus] (NCT06558279)

Currently recruiting

ARISE

Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy [CIDP]

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Currently recruiting
1 2 3 4 5